These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 28838583

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Daniel DG, Currier GW, Zimbroff DL, Allen MH, Oren D, Manos G, McQuade R, Pikalov AA, Crandall DT.
    J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
    [Abstract] [Full Text] [Related]

  • 23. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
    Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH.
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
    [Abstract] [Full Text] [Related]

  • 24. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD.
    Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
    [Abstract] [Full Text] [Related]

  • 25. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
    Risinger R, Hard M, Weiden PJ.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):26-34. PubMed ID: 28839337
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.
    JAMA Psychiatry; 2015 Aug 01; 72(8):830-9. PubMed ID: 25820612
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 01; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 28. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC, González Sánchez L, García Resa E, Bonete Llácer JM, Román Rodríguez A, Pecino Esquerdo B, Pérez Martínez E.
    Int J Psychiatry Clin Pract; 2020 Mar 01; 24(1):10-17. PubMed ID: 31933402
    [Abstract] [Full Text] [Related]

  • 29. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
    Jensen KG, Correll CU, Rudå D, Klauber DG, Decara MS, Fagerlund B, Jepsen JRM, Eriksson F, Fink-Jensen A, Pagsberg AK.
    J Am Acad Child Adolesc Psychiatry; 2019 Nov 01; 58(11):1062-1078. PubMed ID: 30858012
    [Abstract] [Full Text] [Related]

  • 30. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, Iwamoto T.
    Psychopharmacology (Berl); 2006 Oct 01; 188(3):281-92. PubMed ID: 16953381
    [Abstract] [Full Text] [Related]

  • 31. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
    Fleischhacker WW, Sanchez R, Johnson B, Jin N, Forbes RA, McQuade R, Baker RA, Carson W, Kane JM.
    Int Clin Psychopharmacol; 2013 Jul 01; 28(4):171-6. PubMed ID: 23615694
    [Abstract] [Full Text] [Related]

  • 32. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN.
    J Psychiatr Res; 2007 Dec 01; 41(11):895-905. PubMed ID: 17631314
    [Abstract] [Full Text] [Related]

  • 33. Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder.
    Findling RL, Youngstrom EA, McNamara NK, Stansbrey RJ, Wynbrandt JL, Adegbite C, Rowles BM, Demeter CA, Frazier TW, Calabrese JR.
    J Clin Psychiatry; 2012 Jan 01; 73(1):57-63. PubMed ID: 22152402
    [Abstract] [Full Text] [Related]

  • 34. Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence.
    Beresford T, Buchanan J, Thumm EB, Emrick C, Weitzenkamp D, Ronan PJ.
    J Clin Psychopharmacol; 2017 Dec 01; 37(6):657-663. PubMed ID: 28984746
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
    Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK.
    JAMA Psychiatry; 2024 Aug 01; 81(8):749-756. PubMed ID: 38691387
    [Abstract] [Full Text] [Related]

  • 36. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
    Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, Lencz T, Correll CU, Kane JM, Malhotra AK.
    Schizophr Bull; 2015 Nov 01; 41(6):1227-36. PubMed ID: 26338693
    [Abstract] [Full Text] [Related]

  • 37. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.
    J Affect Disord; 2009 May 01; 115(1-2):18-26. PubMed ID: 19230981
    [Abstract] [Full Text] [Related]

  • 38. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.
    Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA.
    Schizophr Res; 2016 Oct 01; 176(2-3):264-271. PubMed ID: 27427558
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
    Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, Yagoda S, Bidollari I, Keane E, Cash E.
    J Clin Psychiatry; 2020 May 19; 81(3):. PubMed ID: 32433835
    [Abstract] [Full Text] [Related]

  • 40. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY, Chung S, Lee JN, Kwon JS, Kim DH, Kim CE, Jeong B, Jeon YW, Lee MS, Jun TY, Jung HY.
    Int Clin Psychopharmacol; 2009 Jul 19; 24(4):181-8. PubMed ID: 19451828
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.